Genentech CFO Lou Lavigne to retire
Thursday, 11 November, 2004
Genentech has announced that its chief financial officer, Lou Lavigne, will retire next March and will be replaced by David Ebersman, currently senior vice president of product operations.
Ebersman joined Genentech in 1994 and was named senior director of product development in 1998, vice president of product development in 1999 and senior vice president of product operations in 2001.
He became a member of Genentech's executive committee in March 2004.
Before joining Genentech, Ebersman was a research analyst covering biotechnology at Oppenheimer & Company, which is now CIBC World Markets. Ebersman will be replaced by Pat Yang, currently vice president of South San Francisco Manufacturing and Engineering.
TGA approves donanemab for treatment of early Alzheimer's
The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
